Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETOX: Switching to Symtuza for HIV-Associated Neurotoxicity
NCT03685500Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of darunavir, cobicistat, emtricitabine, tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Fundación SEIMC-GeSIDA. Started Dec 2018; status: completed.
02
Drugs
darunavircobicistatemtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03685500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685500.